Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
While early-generation nanomedicines (such as liposomal mifamurtide) have historical clinical applications in osteosarcoma, and some nanocarriers like epirubicin micelles (NC-6300) have entered early-phase trials for general sarcomas, none of the advanced, multi-targeted nanomedicine-immunotherapy combination platforms discussed in this review have yet entered active clinical trials specifically for osteosarcoma
doi: 10.1056/NEJMoa1911303 63 PackerMAnkerSDButlerJFilippatosGPocockSJCarsonPet al
The dose number on the opposite side is the primary visual differentiator
Nat Rev Neurosci 13:478490
(Life Sciences) Yuhan Corporation Hanmi Pharmaceutical Co., Ltd
Practical Guidance (Interim) Clinicians should counsel that current evidence does not justify routine therapeutic use outside registered ethically approved research protocols and that online sourcing introduces quality, legal and professional risk
